Insider Trading June 17, 2026 07:47 AM

Kaltura Executive Eynav Azaria Disposes of Shares Under Pre-Existing Trading Arrangement

Analysis of recent insider activity, valuation metrics, and Q1 2026 financial performance for Kaltura Inc.

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
KLTR

Kaltura Inc. (NASDAQ:KLTR) executive Eynav Azaria executed a sale of 19,456 shares on June 15, 2026, under a Rule 10b5-1 trading plan. The transaction occurred amidst broader market analysis suggesting the stock is overvalued relative to its fair value, despite recent revenue beats in the first quarter of 2026.

Kaltura Executive Eynav Azaria Disposes of Shares Under Pre-Existing Trading Arrangement
KLTR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Executive Eynav Azaria sold 19,456 shares for $28,868 under a pre-arranged Rule 10b5-1 plan.
  • Kaltura reported Q1 2026 revenue of $44.6 million, beating expectations of $44.39 million.
  • Analysts maintain price targets of $3 to $4 per share despite current valuation metrics suggesting overvaluation.

Kaltura Inc. (NASDAQ:KLTR) executive Eynav Azaria recently completed a transaction involving the sale of company equity. On June 15, 2026, Azaria sold 19,456 shares of the corporation's common stock. The total monetary value derived from this sale was $28,868. The execution of these shares occurred at a weighted average price of $1.4838. Individual transactions within this block were executed at price points ranging between $1.40 and $1.52 per share. The sales were conducted in accordance with a Rule 10b5-1 trading plan, a mechanism designed to facilitate pre-arranged transactions. Azaria originally adopted this specific trading plan on December 15, 2025.

Following the completion of this sale, Azaria's direct ownership position in Kaltura common stock stands at 2,195,818 shares. Market data indicates the stock is currently trading at $1.45, corresponding to a market capitalization of $218 million. Valuation analysis suggests a divergence between current market pricing and intrinsic value metrics. Specifically, data indicates Kaltura may be overvalued at present levels, with a calculated Fair Value of $1.23. Despite this valuation metric, analyst sentiment remains constructive, with price targets established in the range of $3 to $4 per share.

Recent corporate financial disclosures provide additional context regarding Kaltura's operational standing. The company reported its first-quarter earnings for 2026, revealing financial results that surpassed revenue forecasts. Revenue was recorded at $44.6 million, exceeding the anticipated figure of $44.39 million. Earnings per share aligned with market forecasts at $0.01. The market response to these earnings was cautious, reflecting a nuanced investor reaction to the company's financial performance and strategic initiatives. Strategic investments have been identified as a contributing factor to mixed market signals, prompting close monitoring by investors and analysts evaluating Kaltura's ongoing performance and future potential.

Risks

  • Current market valuation appears elevated relative to calculated fair value of $1.23.
  • Market reaction to Q1 2026 earnings was cautious, indicating mixed investor sentiment despite revenue beats.
  • Strategic investments are contributing to mixed market signals, requiring close monitoring.

More from Insider Trading

Clover Health Finance VP Executes $58,815 Stock Sale Amid Regulatory Victory and Earnings Update Jun 17, 2026 Kaltura Chief Customer Officer Executes Pre-Arranged Sale of Company Shares Jun 17, 2026 OneMedNet Executive Jeffrey Yu Acquires $100,000 Stake Amid Operational Shifts Jun 17, 2026 AMN Healthcare Director Mark Foletta Divests Shares Under Pre-Arranged Plan Jun 17, 2026 BELITE BIO Executive Scholl Offloads $1.4M in Shares Amid Regulatory Milestones Jun 17, 2026